United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 8,000 Shares

United Therapeutics Co. (NASDAQ:UTHRGet Rating) CEO Martine A. Rothblatt sold 8,000 shares of United Therapeutics stock in a transaction on Thursday, January 19th. The stock was sold at an average price of $259.60, for a total value of $2,076,800.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $33,748. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $261.70 on Friday. United Therapeutics Co. has a fifty-two week low of $158.38 and a fifty-two week high of $283.09. The business has a 50-day moving average of $270.84 and a two-hundred day moving average of $241.25. The stock has a market capitalization of $11.93 billion, a P/E ratio of 17.80, a P/E/G ratio of 1.54 and a beta of 0.62. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39.

United Therapeutics (NASDAQ:UTHRGet Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, topping analysts’ consensus estimates of $3.57 by $1.34. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. The company had revenue of $516.00 million during the quarter, compared to analysts’ expectations of $492.92 million. On average, equities research analysts predict that United Therapeutics Co. will post 16.63 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of United Therapeutics by 3.8% in the third quarter. Vanguard Group Inc. now owns 4,411,616 shares of the biotechnology company’s stock worth $923,703,000 after buying an additional 163,542 shares during the last quarter. BlackRock Inc. lifted its position in shares of United Therapeutics by 0.3% during the 3rd quarter. BlackRock Inc. now owns 4,327,368 shares of the biotechnology company’s stock worth $906,061,000 after purchasing an additional 13,196 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of United Therapeutics by 1.0% during the 2nd quarter. Renaissance Technologies LLC now owns 2,793,591 shares of the biotechnology company’s stock worth $658,282,000 after purchasing an additional 28,378 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of United Therapeutics by 73.7% during the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock worth $300,585,000 after purchasing an additional 710,668 shares during the last quarter. Finally, State Street Corp lifted its position in shares of United Therapeutics by 7.2% during the 1st quarter. State Street Corp now owns 1,626,491 shares of the biotechnology company’s stock worth $291,809,000 after purchasing an additional 109,226 shares during the last quarter. Institutional investors and hedge funds own 95.63% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on UTHR. Morgan Stanley lifted their price target on United Therapeutics from $322.00 to $330.00 and gave the company an “overweight” rating in a report on Tuesday, December 6th. UBS Group began coverage on United Therapeutics in a report on Tuesday, December 6th. They set a “buy” rating and a $320.00 price target on the stock. HC Wainwright lifted their price target on United Therapeutics from $255.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, November 3rd. Argus lifted their price target on United Therapeutics from $250.00 to $300.00 and gave the company a “buy” rating in a report on Wednesday, January 11th. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $283.64.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Stories

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.